Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple ascending dose study of ESB1609 in healthy volunteers
NL-OMON55239Phase 1Active, not recruiting
- Sponsor
- ESCAPE Bio, Inc.
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ESB1609 in Niemann-Pick disease type C (NPC), sponsored by ESCAPE Bio, Inc. Primary endpoints: Plasma and cerebrospinal fluid pharmacokinetics of ESB1609 and Safety and tolerability. Started Feb 2020; status: active, not recruiting.
02
Drugs
ESB1609
03
Conditions
Niemann-Pick disease type C (NPC)
Beyond the preview
Go deeper on NL-OMON55239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55239.